PNOC022
Clinical trial of combinations of various agents (in particular dordaviprone/ONC201) for the treatment of diffuse midline gliomas (DMG) in children and young adults
This study offers trial enrollment at different disease stages: newly-diagnosed, after completion of radiation therapy, and at time of progression. ONC201 is an novel therapeutic class and will be used as a backbone for the different trial treatments. ONC201 will be combined with novel agents that have been shown in preclinical studies to be additive or synergistic in combination. This trial will utilize an adaptive platform design in that the different treatment arms for each cohort will be opened and closed based on ongoing preclinical investigation as well as evolving outcome data from the trial, such as blood brain barrier penetration and/or efficacy signals. We aim to understand the effects in DMG tumor tissue for each incorporated therapy and offer combination therapies at different stages of disease. Further, such a facile trial design will allow for rapid incorporation of new agents based on our and others’ preclinical investigations.
Is this study suitable for my child’s condition?
Leukaemia, lymphoma and bone marrow disease
- Acute lymphoblastic leukemia (ALL)
- Acute myeloid leukemia (AML)
- Chronic myeloid leukemia (CML)
- Myelodysplastic syndrome (MDS)
- Severe aplastic anemia (SAA)
- Non-Hodgkin lymphoma
- Hodgkin lymphoma
- Other leukaemia, lymphoma and bone marrow disease
Brain and spinal cord tumors
- Low-grade glioma
- High-grade glioma
- Diffuse-intrinsic pontine glioma (DIPG) / Diffuse midline glioma (DMG)
- Medulloblastoma
- Atypical teratoid rhabdoid tumours (ATRT)
- Ependymoma
- Germ cell tumours / germinoma / nongerminomatous germ cell tumours / teratoma (brain / spinal cord)
- Craniopharyngioma
- Other brain tumours or spinal cord tumours
Solid tumors
- Wilms tumours / nephroblastoma
- Neuroblastoma
- Rhabdomyosarcoma
- Ewing sarcoma
- Osteosarcoma
- Rhabdoid tumours (other than brain or spinal cord)
- Other sarcoma
- Germ cell tumours (other than brain or spinal cord)
- Retinoblastoma
- Hepatoblastoma
- Other solid tumours
Study Information
What age range of children can participate?
2 - 39 years
Official Study Information
Study at www.humanforschung-schweiz.ch
Study at www.clinicaltrials.gov
Questions? Please contact your medical team.
If you would like more information about a study, please speak to your child’s treating physician. They are your primary point of contact and can provide personalized advice and support. If no treatment team is currently in place, you can find general contact information for the study sites on the map below.
Treatment Centers with Open Study – Map & Overview
The map shows all treatment sites in Switzerland. Locations where the study is currently open are marked in blue. You can find contact details by clicking on the towns. The information on study sites is updated regularly. However, a study may occasionally open at a new site before this is reflected on the platform. If in doubt, please contact your treatment team or one of the listed clinics directly.
Zürich
Universitäts-Kinderspital Zürich –
Eleonorenstiftung
Lenggstrasse 30
8008 Zürich
https://www.kispi.uzh.ch
Sekretariat Onkologie
Telefon: +41 44 249 63 50
E-Mail: onkologie.sekretariat@kispi.uzh.ch